Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$125.14 USD

125.14
3,006,201

+3.66 (3.01%)

Updated Jul 16, 2024 04:00 PM ET

Pre-Market: $124.75 -0.39 (-0.31%) 8:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Moderna (MRNA) Stock Moves -1.52%: What You Should Know

Moderna (MRNA) closed at $172.26 in the latest trading session, marking a -1.52% move from the prior day.

Sweta Jaiswal, FRM headshot

Moderna ETFs Rallying on COVID-19 Vaccine Booster Shot Update

Moderna has been rallying on the latest positive booster shot-related update.

Company News for Mar 30, 2022

Companies In The News Are: FDX, UNH, LHCG, MRNA, ESLT.

Kinjel Shah headshot

FDA Authorizes Pfizer, Moderna's Second COVID Booster Dose

The FDA authorized a second booster dose of COVID-19 vaccines made by Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) for older adults and some immunocompromised individuals.

Moderna (MRNA) Gains But Lags Market: What You Should Know

Moderna (MRNA) closed the most recent trading day at $179.68, moving +0.53% from the previous trading session.

Moderna (MRNA) to File EUA for Use of mRNA-1273 in Children

Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.

Novavax's (NVAX) COVID Jab Gets EUA Nod for Kids in India

Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.

Biotech Stock Roundup: BMY's Drug Approval, MRNA's Vaccine Update & More

Pipeline and regulatory updates from Bristol Myers (BMY) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.

Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day

Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day

Pfizer (PFE) Recalls Hypertension Drug Due to Impurities

Pfizer (PFE) is recalling six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.

Kinjel Shah headshot

FDA Panel to Discuss Fourth Booster Dose in April Meeting

The FDA advisory committee meeting on Apr 6 is likely to give an insight into how the regulatory agency feels about the need for additional boosters of COVID-19 vaccines.

The Zacks Analyst Blog Highlights Invesco QQQ, JD.com, MercadoLibre, Moderna, DocuSign, and Baidu

Invesco QQQ, JD.com, MercadoLibre, Moderna, DocuSign, and Baidu have been highlighted in this Analyst Blog.

Moderna (MRNA) Up on FDA Filing for Second COVID Booster Jab

Moderna (MRNA) seeks the FDA's authorization for a fourth dose of its COVID vaccine in adults who already got an initial authorized booster dose of the same in the United States.

Sweta Killa headshot

5 Stocks in Nasdaq ETF That Gained Most Last Week

The Nasdaq Index logged in the best weekly gain since November 2020 fueled by the Fed¿¿¿s decision to raise interest rates for the first time since 2018 and progress in the Russia-Ukraine peace talks

The Zacks Analyst Blog Highlights J&J, Pfizer, BioNTech, and Moderna

J&J, Pfizer, BioNTech, and Moderna have been highlighted in this Analyst Blog.

What's in Store for J&J's (JNJ) Segments & Pipeline in 2022?

J&J's (JNJ) Pharma unit is performing above market levels. The Consumer unit is improving. The Medical Devices unit is being hurt by soft recovery trends in medical procedures.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Moderna (MRNA) closed at $168.26 in the latest trading session, marking a -0.65% move from the prior day.

Moderna (MRNA) Up More Than 30% in 10 Days: What Lies Ahead?

Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.

Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More

Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.

Pfizer, BioNTech Seek FDA Nod for 4th COVID Shot in Older Adults

Pfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.

Sweta Jaiswal, FRM headshot

China's COVID-19 Lockdown Brings Back Focus on Healthcare ETFs

Let's take a look at some healthcare ETFs that are regaining popularity among investors as COVID-19 cases rise in China.

BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?

On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

Moderna (MRNA) Early-Stage HIV Vaccine Study Begins, Stock Up

Moderna (MRNA) starts dosing in an mRNA-based HIV vaccine study.

Moderna (MRNA) Stock Jumps 8.6%: Will It Continue to Soar?

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Moderna (MRNA) Stock Moves -0.95%: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $138.20, marking a -0.95% move from the previous day.